Phase II trial of neoadjuvant chemotherapy with mFOLFOX6 plus Bevacizumab for resectable local recurrent rectal cancer
Phase 2
- Conditions
- Resectable local recurrent rectal cancer
- Registration Number
- JPRN-UMIN000002920
- Lead Sponsor
- agoya Surgical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. Unresectable local recurrent rectal cancer 2. Active infections 3. With brain metastases 4. Severe neuropathy 5. Pregnant 6. Prebious history of severe drug-induced allergy 7. Serious complications 8. With interstitial lung disease or pulmonary fibrosis 9. Multiple malignancies to be treated 10. Uncontrollable peptic ulcer disease 11. Disqualified by attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease free survival
- Secondary Outcome Measures
Name Time Method overall survival, R0 resection rate